Prof. Dr. Aslı ÇİFCİBAŞI ÖRMECİ

Yayın Ağı

Makaleler 60

1. Extra intestinal manifestations may increase the risk of synchronous and metachronous development of other extraintestinal manifestations in patients with Crohn’s disease

Ozkahraman A., Kayar Y., Dertli R., Konur S., Kılıc G., Baran B., et al.

Scientific Reports , cilt.15, sa.1, 2025 (SCI-Expanded)

2. A prospective study on the role of non-invasive tests in the evaluation of diabetes mellitus associated steatotic liver disease

İstemihan Z., Bektaş F., Bardak A. E., Kızıltaş C., Kemeç G., İmanov Z., et al.

Scientific Reports , cilt.15, sa.1, 2025 (SCI-Expanded)

3. Anxiety and Depression Outcomes in Liver Transplant Candidates and Recipients Using the Hospital Anxiety and Depression Scale

Bardak A. E., Cifcibasi Ormeci A., Yildiz Z., Senkal V., Imanov Z., Istemihan Z., et al.

Transplantation Proceedings , cilt.57, sa.6, ss.1170-1175, 2025 (SCI-Expanded) Sürdürülebilir Kalkınma

4. The role of GALAD score in the surveillance of hepatocellular carcinoma.

İstemihan Z., Şenkal İ. V., Karaca D., Nurıyev K., Rustamzade A., Genç Uluçeçen S., et al.

Scientific reports , cilt.15, sa.1, ss.22279, 2025 (SCI-Expanded)

5. The Role of Pancreatic Enzyme Insufficiency in the Etiology of Functional Dyspepsia Resistant to Standard Treatment

kemik f., CEYLAN G., Aydın A. F., Çavuş B., Ormeci A., Imanov Z., et al.

Turkish Journal of Gastroenterology , cilt.36, sa.7, ss.467-473, 2025 (SCI-Expanded)

6. “Liver-Related Mortality in Type 2 Diabetes: Important Insights and Methodological Considerations”

Gurbanov A., Genç Uluçeçen S., Çifçibaşi Örmeci A.

Liver International , cilt.45, sa.6, 2025 (SCI-Expanded)

7. Encapsulating Peritoneal Sclerosis: The Consequence of Recurrent Spontaneous Bacterial Peritonitis

Bardak A. E., Selvi B., Poyanlı A., Çifçibaşı Örmeci A.

Digestive Diseases and Sciences , cilt.70, sa.2, ss.443-444, 2025 (SCI-Expanded)

8. Decisional Control Preferences in Managing Intraductal Papillary Mucinous Neoplasms of the Pancreas

Ağargün B. F., Dağcı G., Çavuş B., Çifcibaşı Örmeci A.

Pancreas , 2025 (SCI-Expanded)

9. What are the predictors of malignancy in inflammatory bowel disease?

İstemihan Z., Çavuş B., Bardak A. E., Kirkoğlu A. M., Kiziltaş C., Silay R., et al.

Turkish Journal of Medical Sciences , cilt.55, sa.4, ss.846-854, 2025 (SCI-Expanded)

10. Virological and Biochemical Effects of Tenofovir Alafenamide in Different Patient Groups With Chronic Hepatitis B Virus Infection in Real-World Cohort

Bektas E., Yilmaz A., Kikili C. I., Nuriyev K., Istemihan Z., Senkal I. V., et al.

International Journal of Hepatology , cilt.2025, sa.1, 2025 (ESCI)

11. Lumen-apposing metal stents for pancreatic fluid collections: has advancing technology encouraged over-reach?

Ağargün B. F., Cavus B., Cifcibasi Ormeci A., Demir K.

Gut , 2025 (SCI-Expanded)

12. Aceruloplasminemia as a rare hereditary disease: four case reports in a single center

İstemihan Z., İmanov Z., Çavuş B., Çifcibaşı Örmeci A., Akyüz F., Beşışık S. F., et al.

Baylor University Medical Center Proceedings , sa.0, ss.1-4, 2024 (Scopus)

13. Changing Trends in the Etiology of Cirrhosis in Türkiye: A Multicenter Nationwide Study

Üçbilek E., Yıldırım A. E., Ellik Z., Turan İ., Haktanıyan B., Orucu B., et al.

Turkish Journal of Gastroenterology , cilt.35, sa.10, ss.772-777, 2024 (SCI-Expanded) Sürdürülebilir Kalkınma

14. Two Cases of Malignant Transformation in Crohn’s Disease with Perianal Involvement

DAĞCI G., VARELCİ S., BÜYÜK M., ÇAVUŞ B., ÇİFCİBAŞI ÖRMECİ A., AKYÜZ F., et al.

Kare Publishing , cilt.2, 2023 (Hakemli Dergi)

15. Is the Y90-radioembolization treatment effective on the intermediate-advanced stage of hepatocellular carcinoma and what is the albumin-bilirubin score’s prediction factor for survival?

Evirgen S., ÇAVUŞ B., Gokturk S., Iliaz R., ÖZKAN Z. G., Baran B., et al.

Hepatology Forum , cilt.4, sa.3, ss.103-107, 2023 (Scopus)

16. Different Faces of Eosinophilic Infiltration of Gastrointestinal System

İSTEMİHAN Z., ÇAVUŞ B., BERKER N., Nuriyev K., Şenkal V., İmanov Z., et al.

Journal of Enterocolitis , cilt.1, sa.3, ss.68-71, 2022 (Hakemli Dergi)

17. Mucocutaneous Manifestations and Associated Factors in Patients with Crohn's Disease

Kayar Y., Dertli R., Konür Ş., Ağın M., Al Kafee A., Baran B., et al.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , cilt.33, sa.11, ss.945-954, 2022 (SCI-Expanded)

18. What is the effect of subepithelial lesions of the esophagus on esophageal motility?

Oermeci A., Cavus B., Akas R., Istemihan Z., Imanov Z., Senkal V., et al.

European review for medical and pharmacological sciences , cilt.26, sa.17, ss.6300-6309, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

19. Is anterior segment OCT superior to slit-lamp biomicroscopic examination for Kayser Flesicher ring in Wilson's disease?

Ormeci A., Bayraktar S., Isik A. O., Cavus B., Akas R., Istemihan Z., et al.

European review for medical and pharmacological sciences , cilt.26, sa.14, ss.5178-5185, 2022 (SCI-Expanded)

20. Cyclosporine Therapy as a Rescue Treatment in Steroid Refractory Acute Severe Ulcerative Colitis: A Real Life Data From a Tertiary Center

Evirgen S., Iliaz R., Akyuz F., Cavus B., Gokturk S., Ormeci A., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.33, sa.6, ss.463-469, 2022 (SCI-Expanded)

21. Are Hepatobiliary Manifestations Related to the Site of Involvement in Inflammatory Bowel Disease?

İstemihan Z., Çifcibaşı Örmeci A., Çavuş B., Şenkal İ. V., İmanov Z., Nuriyev K., et al.

Journal of Enterocolitis , cilt.1, ss.12-16, 2022 (Hakemli Dergi)

22. EVALUATION OF HELICOBACTER PYLORI FREQUENCY AND GASTRIC ANTRUM PATHOLOGY FINDINGS IN PATIENTS WITH PORTAL HYPERTENSION

Cavus B., Ormeci A., Evirgen S., Iliaz R., Atasoy A., Yegen G., et al.

JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI , cilt.85, sa.2, ss.211-215, 2022 (ESCI)

23. Can Interferon Therapy Change the Natural Course of Hepatitis Delta Infection?: a Clinical and Pathological Study

BAKKALOĞLU O. K., Yildirim O., Cavus B., Evirgen S., Gokturk S., Ormeci A., et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , cilt.66, sa.1, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

24. A mysterious cause of recurrent acute liver dysfunction for over a decade

Dirim A. B., Kalayci T., Guzel Dirim M., Demir S., Cavus B., Cifcibasi Ormeci A., et al.

GASTROENTEROLOGY REPORT , cilt.10, 2022 (SCI-Expanded)

25. The Relationship between Ocular Vascular Changes and the Levels of Malondialdehyde and Vascular Endothelial Growth Factor in Patients with Inflammatory Bowel Disease

Sengul S., Poturoglu S., Samanci C., Ustabasioglu F., Koldas M., Duman A., et al.

OCULAR IMMUNOLOGY AND INFLAMMATION , cilt.29, sa.7-8, ss.1459-1463, 2021 (SCI-Expanded)

26. ANALYSIS OF GENOTYPE, SUBGENOTYPE AND SEROTYPE OF OCCULT HEPATITIS B VIRUS

Cakal B., Atasoy A., Cavus B., Ormeci A., Poda M., Bulakci M., et al.

JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI , cilt.84, sa.3, ss.402-410, 2021 (ESCI) Sürdürülebilir Kalkınma

27. Etiology of Cirrhosis in Turkey: A National Cohort Study

YILDIRIM A. E., ÜÇBİLEK E., Oruncu M. B., TURAN İ., DEMİR M., Koksal A., et al.

JOURNAL OF HEPATOLOGY , cilt.75, 2021 (SCI-Expanded)

28. The development of extraintestinal manifestation and related risk factors in Crohn's patients

Kayar Y., Dertli R., Konur S., Agin M., Baran B., Ormeci A., et al.

IRISH JOURNAL OF MEDICAL SCIENCE , cilt.190, sa.2, ss.597-604, 2021 (SCI-Expanded)

29. What are the predictors for recurrence of Crohn's disease after surgery?

Ozgur İ., Kulle C. B., Buyuk M., Ormeci A., Akyuz F., Balik E., et al.

MEDICINE , cilt.100, sa.14, 2021 (SCI-Expanded)

30. Myeloma and Cystoisospora belli REPLY

Tiryaki T. O., Anil K. U., Buyuk M., Yildirim A. Y., Atasoy A., Ormeci A., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.38, sa.3, ss.230, 2021 (SCI-Expanded)

31. IMPLICATION OF SERUM IL-17 LEVELS IN CHRONIC HEPATITIS B PATIENTS

ÇAKAL B., ÇAVUŞ B., Atasoy A., Ormeci A., BULAKÇI M., GÜLLÜOĞLU M., et al.

JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI , cilt.84, sa.1, ss.68-75, 2021 (ESCI)

32. Prolonged Severe Watery Diarrhea in a Long-Term Myeloma Survivor: An Unforeseen Infection with Cystoisospora belli

Tiryaki T. O., Anıl K. U., Büyük M., Yıldırım A. Y., Atasoy A., Çiftçibaşı Örmeci A., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.38, sa.2, ss.171-173, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

33. The effect of liver test abnormalities on the prognosis of COVID-19.

Medetalibeyoglu A., Catma Y., Senkal N., Ormeci A., Cavus B., Kose M., et al.

Annals of hepatology , cilt.19, sa.6, ss.614-621, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

34. Efficacy of adalimumab in mild-to-moderate inflammatory bowel disease: Real-life data from single-centre experience in the long-term period

Akyuz F., Ormeci A., Namazova N., Guzel M., Abbasgoulizadeh A., Tahincioglu L., et al.

JOURNAL OF CROHNS & COLITIS , 2020 (SCI-Expanded)

35. Gastroesophageal Reflux in Asymptomatic Patients with Diabetes: An Impedance Study Diabetes, Obesity and Gastroesophageal Reflux

Gokturk S., Akyuz F., Arici S., Alpaslan B., Ormeci A., Soyer O. M., et al.

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES , cilt.128, sa.1, ss.52-58, 2020 (SCI-Expanded) Sürdürülebilir Kalkınma

36. Risk factors associated with progression to intestinal complications of Crohn disease

Kayar Y., Baran B., Ormeci A., Akyuz F., Demir K., Besisik F., et al.

CHINESE MEDICAL JOURNAL , cilt.132, sa.20, ss.2423-2429, 2019 (SCI-Expanded)

37. Usage of HCV viremic organs in liver transplantation to anti-HCV negative recipients: The current status and review of literature

ÇİFCİBAŞI ÖRMECİ A., Yildiz C., Seberi B., Gurakar M., Simsek C., Gurakar A.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.30, sa.9, ss.771-775, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma

38. Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?

Akyuz F., Cavus B., Iliaz R., Soyer O. M., Ormeci A., Evirgen S., et al.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.31, sa.7, ss.777-780, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma

39. Does the number of mucosal immune cells differ in irritable bowel syndrome and its subtypes?

İLIAZ R., AKYÜZ F., Yeğen G., ÖRMECI A., GÖKTÜRK S., AKYÜZ Ü., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.29, sa.4, ss.384-391, 2018 (SCI-Expanded)

40. Current state and clinical outcome in Turkish patients with hepatocellular carcinoma

Ekinci O., Baran B., Ormeci A., Soyer O. M., Gokturk S., Evirgen S., et al.

WORLD JOURNAL OF HEPATOLOGY , cilt.10, sa.1, ss.51-61, 2018 (ESCI)

41. Role of biochemistry and cytological analysis of cyst fluid for the differential diagnosis of pancreatic cysts A retrospective cohort study

Soyer O. M., Baran B., Ormeci A., Sahin D., Gokturk S., Evirgen S., et al.

MEDICINE , cilt.96, sa.1, 2017 (SCI-Expanded)

42. A rare congenital liver anomaly: Hypoplasia of left hepatic lobe

Ormeci T., Erdogan S. T., ÇİFCİBAŞI ÖRMECİ A., Aygun C.

JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION , cilt.66, sa.12, ss.1662-1664, 2016 (SCI-Expanded)

43. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels

Ormeci A., Aydın Y., Sumnu A., Baran B., Soyer O. M., Pinarbasi B., et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES , cilt.52, ss.68-73, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma

44. Retention during capsule endoscopy: Is it a real problem in routine practice?

Ormeci A., Akyuz F., Baran B., Gokturk S., Ormeci T., Pinarbasi B., et al.

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH , cilt.44, sa.4, ss.968-975, 2016 (SCI-Expanded)

45. Comparison of the efficacy of 12 months and longer courses of interferon therapy for the treatment of chronic delta hepatitis: a retrospective cohort study

Soyer O. M., Baran B., Ormeci A., Gokturk S., Aydin E., Onel D., et al.

POSTGRADUATE MEDICINE , cilt.128, sa.4, ss.432-438, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma

46. Can Helicobacter pylori be eradicated with high-dose proton pump inhibitor in extensive metabolizers with the CYP2C19 genotypic polymorphism?

ORMECI A., Emrence Z., BARAN B., SOYER O., GOKTURK S., EVIRGEN S., et al.

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES , cilt.20, sa.9, ss.1795-1797, 2016 (SCI-Expanded)

47. What is the impact of capsule endoscopy in the long term period?

Ormeci A., Akyuz F., Baran B., Gokturk S., Ormeci T., Pinarbasi B., et al.

WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY , cilt.8, sa.7, ss.344-348, 2016 (ESCI)

48. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole

Ormeci A., Emrence Z., Baran B., Gokturk S., Soyer O. M., Evirgen S., et al.

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES , cilt.20, sa.5, ss.879-885, 2016 (SCI-Expanded)

49. Steroid-refractory inflammatory bowel disease is a risk factor for CMV infection

Ormeci A., Akyuz F., BARAN B., SOYER O., GÖKTÜRK S., ONEL M., et al.

European Review for Medical and Pharmacological Sciences , cilt.20, sa.5, ss.858-865, 2016 (SCI-Expanded)

50. Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus

Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Akyuz F., et al.

LIVER INTERNATIONAL , cilt.35, sa.10, ss.2265-2274, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

51. Small bowel mucosal damage in familial Mediterranean fever: results of capsule endoscopy screening

Demir A., Akyuz F., Gokturk S., Evirgen S., Akyuz U., Ormeci A., et al.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.49, sa.12, ss.1414-1418, 2014 (SCI-Expanded)

52. Effects of Polymorphisms in Interferon lambda 3 (Interleukin 28B) on Sustained Virologic Response to Therapy in Patients With Chronic Hepatitis D Virus Infection

Yilmaz E., Baran B., Soyer O. M., Onel M., Onel D., Ormeci A., et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY , cilt.12, sa.10, ss.1753-1758, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

53. Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma

Karabulut S., Tas F., Akyuz F., Ormeci A., Serilmez M., Soydinc H. O., et al.

TUMOR BIOLOGY , cilt.35, sa.3, ss.2327-2333, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

54. Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C

Baran B., Gulluoglu M., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., et al.

JOURNAL OF VIRAL HEPATITIS , cilt.21, sa.2, ss.111-120, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

55. Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B

KESKİN O., Ormeci A., Baran B., Kabacam G., Tuzun A., Karatayli E., et al.

ANTIVIRAL THERAPY , cilt.19, sa.6, ss.543-550, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

56. Effect of Genotypic Differences in CYP2C19 and on Cure Rates for Helicobacter pylori Infection by Triple Therapy With Different Proton Pump Inhibitors

Demir K., ORMECI A., Emrence Z., Gokturk S., Baran B., SOYER O. M., et al.

GASTROENTEROLOGY , cilt.144, sa.5, 2013 (SCI-Expanded)

57. Efficacy of Tenofovir in Patients with Lamivudine Failure Is Not Different from That in Nucleoside/Nucleotide Analogue-Naive Patients with Chronic Hepatitis B

Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Bozbey H. U., et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , cilt.57, sa.4, ss.1790-1796, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

58. Efficacy of pegylated interferon-alpha treatment for 24 months in chronic delta hepatitis and predictors of response

Karaca C., Soyer O. M., Baran B., Ormeci A., Gokturk S., Aydin E., et al.

ANTIVIRAL THERAPY , cilt.18, sa.4, ss.561-566, 2013 (SCI-Expanded)

59. Treatment of aortic valve stenosis and gastrointestinal bleeding by transcatheter aortic valve implantation in Heyde syndrome

Gul M., Surgit O., Ozal E., Ormeci A., Bakir I.

ANADOLU KARDIYOLOJI DERGISI-THE ANATOLIAN JOURNAL OF CARDIOLOGY , cilt.12, sa.8, ss.691-693, 2012 (SCI-Expanded)

60. A rare complication of interferon treatment: optic neuropathy

Gokturk S., Atay K., ÇİFCİBAŞI ÖRMECİ A., Baran B., Soyer O. M., AKYÜZ F., et al.

ANNALS OF GASTROENTEROLOGY , cilt.24, sa.4, ss.335, 2011 (ESCI)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 34

1. Steatotic liver disease in diabetic patients: more serious diabetes mellitus, more serious liver disease

İstemihan Z., Bektaş F., Bardak A. E., Kızıltaş C., Kemeç G., Nurıyev K., et al.

EASL Congress 2024, Milan, İtalya, 5 - 08 Haziran 2024, ss.551, (Özet Bildiri)

2. The relationship between spleen stiffness and portal hypertension liver transplant patients

Nurıyev K., İstemihan Z., Telli P., Qurbanov A., Yağlı M. A., Dağcı G., et al.

EASL Congress 2024, Milan, İtalya, 5 - 08 Haziran 2024, ss.377-378, (Özet Bildiri)

3. 10-year results under tenofovir disoproxil fumarate and entecavir in chronic hepatitis B; HBV clearance rare, disease outcomes good

İstemihan Z., Kemeç G., Cebeci T., Çetin O., Genç Uluçeçen S., Rüstemzade A., et al.

EASL Congress 2024, Milan, İtalya, 5 - 08 Haziran 2024, ss.803, (Özet Bildiri)

4. Clinical characteristics of patients with hereditary hemorrhagic telangiectasia: Real-life data, single-center experience

İstemihan Z., Bardak A. E., Nurıyev K., Rüstemzade A., Genç Uluçeçen S., Çavuş B., et al.

ESGE Days 2024, Berlin, Almanya, 25 - 27 Nisan 2024, ss.297, (Özet Bildiri)

5. Wilson Hastalığında Aile İçi Genetik Taramanın Kliniğe Önemli Katkıları

Şahin A., ÇİFCİBAŞI ÖRMECİ A., SUER İ., DEMİR K., KALAYCI T., ÇEFLE K., et al.

40. Ulusal Gastroenteroloji Haftası ve 11. Gastroenteroloji Cerrahisi Kongresi, Antalya, Türkiye, 21 - 26 Kasım 2023, (Özet Bildiri)

6. Otoimmün Tanılı Hastalarda Viral Serolojik Profilin Değerlendirilmesi

Küçükkaya S., Çaklovica Küçükkaya İ., Çavuş B., Safran N., Önel M., Kırkoyun Uysal H., et al.

7. Ulusak Klinik Mikrobiyoloji Kongresi (KLİMUD), Muğla, Türkiye, 1 - 05 Kasım 2023, ss.635, (Özet Bildiri)

7. ARE THERE NEW PRACTICAL MARKERS TO PREDICT MALIGNANCY IN PANCREATIC CYST FLUIDS?

Anıl K. U., Çavuş B., Çifcibaşı Örmeci A., İmanov Z., Şenkal İ. V., Nurıyev K., et al.

Digestive Disease Week 2023, Washington, Amerika Birleşik Devletleri, 6 - 09 Mayıs 2023, ss.774, (Özet Bildiri)

8. Tedavi naif ve deneyimli Kronik Hepatit B hastalarında tenofovir alafenamidin gerçek yaşam verileri: daha fazla etki, daha az yan etki

Bektaş E., Yılmaz A., Kıkılı C. İ., Nurıyev K., İstemihan Z., Şenkal İ. V., et al.

39. Ulusal Gastroenteroloji Haftası ve 10. Gastroenteroloji Cerrahisi Kongresi, Antalya, Türkiye, 22 - 27 Kasım 2022, ss.1159-1162, (Özet Bildiri)

9. HEMOFAGOSİTİK LENFOHİSTİYOSİTOZUN NADİR BİR SEBEBİ: VİSSERAL LEİSHMANİASİS

Yılmaz A., Bektaş E., Bilgin E., Şenkal İ. V., Çavuş B., Çifcibaşı Örmeci A., et al.

24. Ulusal İç Hastalıkları Kongresi, Antalya, Türkiye, 19 - 23 Ekim 2022, ss.118-119, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

10. GRANÜLOMATÖZ HEPATİT VE İNTRAHEPATİK KOLESTAZA BAĞLI HİPERLİPİDEMİ İLE SEYREDEN AKCİĞER-DIŞI SARKOİDOZ OLGUSU

Bektaş E., Yılmaz A., Bilgin E., Mutlu Ü., Çavuş B., Çifcibaşı Örmeci A., et al.

24. Ulusal İç Hastalıkları Kongresi, Antalya, Türkiye, 19 - 23 Ekim 2022, ss.136-137, (Tam Metin Bildiri)

11. REAL-WORLD DATA OF TENOFOVIR ALAFENAMIDE IN TREATMENT-NAIVE AND EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS B: MORE EFFICACY, LESS SIDE EFFECTS

Bektaş E., Yılmaz A., Kıkılı C. İ., Nurıyev K., İstemihan Z., Şenkal İ. V., et al.

AASLD Liver Meeting , District Of Columbia, Amerika Birleşik Devletleri, 4 - 08 Kasım 2022, cilt.76, ss.299, (Özet Bildiri)

12. Dekompanse karaciğer sirozunda ince barsak tutulumlu diffüz büyük b hücreli lenfoma olgusu

Teberik Kama E., İstemihan Z., Çifcibaşı Örmeci A., Akyüz F., Kaymakoğlu S.

24. Ulusal İç Hastalıkları Kongresi, Antalya, Türkiye, 19 - 23 Ekim 2022, ss.140, (Özet Bildiri)

13. İshal ve kilo kaybının nadir bir nedeni:Amiloidoz

Çiftçi A. C., Konyaoğlu H., Şenkal İ. V., Çavuş B., Çifcibaşı Örmeci A., Akyüz F., et al.

21. Çapa Gastroenteroloji Günleri, İstanbul, Türkiye, 31 Mart - 02 Nisan 2022, ss.70, (Tam Metin Bildiri)

14. Budd-Chiari Sendromu’nda Hepatoselüler Kanser ve Mortalitenin Değerlendirilmesi

İstemihan Z., Nurıyev K., Şenkal İ. V., İmanov Z., Sarıdal M. K., Akas R., et al.

38. Ulusal Gastroenteroloji Haftası, 9. Gastroenteroloji Cerrahisi Kongresi, Antalya, Türkiye, 16 - 21 Kasım 2021, ss.219, (Özet Bildiri) Sürdürülebilir Kalkınma

15. Ön Segment Optik Koherans Tomografi (OCT), Wilson hastalığı tanısında Kayser Fleischer Halkası varlığını değerlendirmeki yeri - Ehil oftalmolog gerekliliğine son verecek mi?

Çifcibaşı Örmeci A., Bayraktar Ş., Işık A. O., İstemihan Z., Sarıdal M. K., Akas R., et al.

38. Ulusal Gastroenteroloji Haftası, 9. Gastroenteroloji Cerrahisi Kongresi, Antalya, Türkiye, 16 - 21 Kasım 2021, ss.218, (Özet Bildiri)

16. Girişimsel Gastroenterolojik İşlemlerde Hastaların Doktor Tercihinde Cinsiyet Önemli mi?

Kara İnci A., Zaralı S., Akyüz M., İmanov Z., Şenkal İ. V., İstemihan Z., et al.

38. Ulusal Gastroenteroloji Haftası, 9. Gastroenteroloji Cerrahisi Kongresi, Antalya, Türkiye, 16 - 21 Kasım 2021, ss.204, (Tam Metin Bildiri)

17. COMPARISON OF PROGNOSTIC SCORING SYSTEMS FOR PREDICTION OF SURVIVAL IN HEPATOCELLULAR CARCINOMA

Baran B., Ekinci O., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., et al.

EASL International Liver Congress, Barcelona, İspanya, 13 - 17 Nisan 2016, (Özet Bildiri) Sürdürülebilir Kalkınma

18. Chronic Renal Failure after Liver Transplantation in Long Term: Prevalence and Risk Factors.

Gokturk S., Baran B., Ormeci A., Soyer O., Evirgen S., Ozden I., et al.

Joint International Congress of ILTS, ELITA and LICAGE, London, Kanada, 4 - 07 Haziran 2014, cilt.20, (Özet Bildiri)

19. Evaluation of Small Bowel Mucosal Damage by Capsule Endoscopy in Familial Mediterranean Fever Patients

Demir A., Besisik F., Gokturk S., Evirgen S., Akyuz U., Ormeci A., et al.

55th Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT) / Digestive Disease Week (DDW), Illinois, Amerika Birleşik Devletleri, 3 - 06 Mayıs 2014, cilt.146, (Özet Bildiri)

20. Is Diabetes Mellitus a Risk Factor for Gastroesophageal Reflux?

Gokturk S., Besisik F., Arici S., Alpaslan B., Ormeci A., Soyer O. M., et al.

55th Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT) / Digestive Disease Week (DDW), Illinois, Amerika Birleşik Devletleri, 3 - 06 Mayıs 2014, cilt.146, (Özet Bildiri) Sürdürülebilir Kalkınma

21. ENTECAVIR AND TENOFOVIR HAVE A COMPARABLE EFFICACY IN TREATMENT OF NUCLEOS(T)IDE ANALOGUE NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A REAL LIFE EXPERIENCE

Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Akyuz F., et al.

49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver, London, Kanada, 9 - 13 Nisan 2014, (Özet Bildiri)

22. Baseline alfa-fetoprotein level is a strong predictor of vascular invasion and survival in patients with hepatocellular carcinoma

Ekinci O., Baran B., Ormeci A., Soyer O. M., Gokturk S., Poyanli A., et al.

64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 Kasım 2013, cilt.58, (Özet Bildiri)

23. Risk factors for significant liver fibrosis in genotype D HBeAg-negative chronic hepatitis B infection with persistently normal ALT and high serum HBVDNA levels

Ormeci A., Akyuz F., Baran B., Soyer O. M., Gokturk S., Karaca C., et al.

64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 Kasım 2013, (Özet Bildiri) Sürdürülebilir Kalkınma

24. The antiviral efficacy of entecavir is not influenced by prior treatment with nucleos(t)ide analogues in patients with chronic hepatitis B

Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Akyuz F., et al.

64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 Kasım 2013, (Özet Bildiri)

25. Tenofovir disoproxil fumarate has a substantial efficacy against adefovir and multi-drug resistant strains of hepatitis B virus

Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Akyuz F., et al.

64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 Kasım 2013, (Özet Bildiri) Sürdürülebilir Kalkınma

26. Virological Supression Does not Prevent the Development of Hepatocellular Carsinoma in Cirrhotic Patients with Genotype D Hepatitis B Infection

Gokturk S., Basar R., Ucar A. R., Basgoze B. H., Altinkaynak M., Buyukballi P., et al.

64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 Kasım 2013, cilt.58, (Özet Bildiri) Sürdürülebilir Kalkınma

27. Safety of Tenofovir in Renal Transplanted and Hemodialysis Patients with Chronic Hepatitis B

Akyuz F., Gokturk S., Baran B., Ormeci A., Soyer O. M., Evirgen S., et al.

64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 Kasım 2013, cilt.58, (Özet Bildiri) Sürdürülebilir Kalkınma

28. IL28B Polymorphisms and Influence on Sustained Virological Response to Interferon Therapy in Chronic DELTA Hepatitis

Karaca C., Yilmaz E., Soyer O. M., Onel D., ÖNEL M., Baran B., et al.

Digestive Disease Week / 28th Annual Residents and Fellows Research Conference of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT), Florida, Amerika Birleşik Devletleri, 18 - 21 Mayıs 2013, cilt.144, (Özet Bildiri) Sürdürülebilir Kalkınma

29. Does Chemoprophylaxis Prevent Tuberculosis Reactivation in the Long Term Period of Anti-TNF Treatment?

AKYÜZ F., Soyer O. M., Gokturk S., ÇİFCİBAŞI ÖRMECİ A., Evirgen S., Onder S. Y., et al.

30. TREATMENT FAILURE MAY LEAD TO ACCELERATED FIBROSIS PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C

Baran B., Gulluoglu M., Soyer O., Ormeci A., Gokturk S., Evirgen S., et al.

International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Hollanda, 24 - 28 Nisan 2013, (Özet Bildiri)

31. Number connection test-A and inhibitor control test are not efficient for diagnosis of minimal hepatic encephalopathy in cirrhotic patients

Baran B., Ozcan E., Oztop N., Cakmak R., Soyer O. M., Ormeci A., et al.

63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 9 - 13 Kasım 2012, cilt.56, (Özet Bildiri)

32. Response to tenofovir treatment of treatment-naive and adefovir experienced patients with chronic hepatitis b

KESKİN O., Ormeci A., Kabacam G., Akyuz F., Aniktar H., Karaca C., et al.

63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 9 - 13 Kasım 2012, cilt.56, (Özet Bildiri) Sürdürülebilir Kalkınma

33. Success of Two Different Endoscopic Submucosal Resection Methods in Gastric Subepithelial Lesions

Karaca C., Soyer O. M., Akyuz F., Baran B., Ormeci A., Gokturk S., et al.

Digestive Disease Week (DDW), California, Amerika Birleşik Devletleri, 19 - 22 Mayıs 2012, cilt.75, ss.136, (Özet Bildiri)

34. RESPONSE TO TENOFOVIR TREATMENT OF TREATMENT-NAIVE VS ADEFOVIR-RESISTANT VS SUBOPTIMAL RESPONDER PATIENTS WITH CHRONIC HEPATITIS B

Keskin O., Ormeci A., Kabacam G., Akyuz F., Aniktar H., Karaca C., et al.

47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Barcelona, İspanya, 18 - 22 Nisan 2012

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

383

H-İndeks (WoS)

Atıf (Scopus)

416

H-İndeks (Scopus)

Atıf (Scholar)

127

H-İndeks (Scholar)

Atıf (TrDizin)

H-İndeks (TrDizin)

Atıf (Diğer Toplam)

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Atıf (Scholar)

H-İndeks (Scholar)

Atıf (TrDizin)

H-İndeks (TrDizin)

Atıf (Diğer Toplam)

Açık Erişim